For localized information and support, would you like to switch to your country-specific website for {0}?
cobas® liat SARS-CoV-2 v2
nucleic acid test
IVD
For in vitro diagnostic use.
Accurate testing for informed health decisions
SARS-CoV-2 can be challenging for clinicians to diagnose based on symptoms alone, as many infected patients may be asymptomatic. Comprehensive testing is essential for diagnosing both symptomatic individuals and those suspected of having COVID-19 to prevent health complications and community spread.1
Although anyone can contract a respiratory virus infection, certain groups are particularly vulnerable to severe disease, including the elderly, young children, and immunocompromised individuals.2 Therefore, there is a continual need for fast and accurate diagnostic tools.
The cobas® liat SARS-CoV-2 v2 nucleic acid test is an automated real-time reverse transcription polymerase chain reaction (RT-PCR) test that detects SARS-CoV-2 in just 20 minutes from a nasal or nasopharyngeal swab sample.3 These rapid test results can guide clinical decisions on patient treatment and isolation precautions for effective infection control. With the reliable and prompt performance of the cobas liat SARS-CoV-2 v2 nucleic acid test, healthcare providers on the front line can swiftly obtain the critical information needed to effectively and efficiently manage patients.
What’s new in version 2?
As viruses continue to evolve, so too must our diagnostic tools. Version 2 of the cobas liat SARS-CoV-2 nucleic acid test builds on the trusted performance of version 1.
- Improved inclusivity for all SARS-CoV-2 targets with updated dual target design, primers, and probes predicted by in silico analysis to detect the most recent sequences from SARS-CoV-2 infections in humans4
cobas liat SARS-CoV-2 v2 nucleic acid test clinical performance
View Full Tablecobas liat SARS-CoV-2 v2 nucleic acid test clinical performance
| Nasopharyngeal swab* | Nasal swab* | ||||
PPA (95% CI) |
NPA (95% CI) | PPA (95% CI) |
NPA (95% CI) | LoD** (TCID50/mL) | |
Symptomatic subjects |
94.5% (90.7-96.8) | 97.6% (96.7-98.3) | 96.7% (93.4-98.4) |
97.2% (96.2- 97.9) |
0.0350 |
Asymptomatic subjects |
86.1% (76.3-92.3) |
97.9% (97.2-98.4) |
89.5% (78.9-95.1) |
98.3% (97.7-98.7) |
**Strain reference: SARS-CoV-2: USA-WA1/2020
cobas liat SARS-CoV-2 v2 nucleic acid test specifications
View Full Tablecobas liat SARS-CoV-2 v2 nucleic acid test specifications
Instrument |
cobas® liat system |
Targets |
SARS-CoV-2 |
Sample type |
Nasopharyngeal (NPS) and nasal swabs (NS) |
Collection media |
VTM, UTM and Saline |
Sample extraction |
Fully automated and integrated |
Technology |
Real-time RT-PCR |
Control |
Internal sample processing control, positive and negative controls |
Time to result |
~20 min |
Reagents |
Ready-to-use, pre-packed tube format |
Kit Storage |
2-8°C |
Registration |
IVDR and 510(k)/ CLIA-waived |
Use left and right arrow keys to scroll between the tabs
Overview
Technical Documents
Access important product documentation including relevant certificates and other resources.
After clicking below, you will be redirected to eLabDoc, where you can select your local country-specific documents.
Related products
References
- Bray L et al. Misdiagnoses in the Context of Suspected Pandemic Influenza or Coronavirus Disease 2019: A Systematic Review. Open Forum Infect Dis. 2022;9(11):ofac515.
- CDC Respiratory Illnesses. [Internet; cited 2025 March] Available from: https://www.cdc.gov/respiratory-viruses/risk-factors/index.html
- F. Hoffmann-La Roche Ltd. Data on file. cobas® liat SARS-CoV-2 CE-IVD Instructions for Use 10162562001-01EN.
- F. Hoffmann-La Roche Ltd. Data on file. Improved Inclusivity and Target Coverage in CFRA Compared to FRTA and SCFA Assays for SARS-CoV-2, Flu A/B, and RSV.